COGT
Price
$7.58
Change
+$0.17 (+2.29%)
Updated
Jul 3 closing price
Capitalization
863.03M
37 days until earnings call
MEOBF
Price
$0.96
Change
-$0.00 (-0.00%)
Updated
Jun 23 closing price
Capitalization
1.36B
52 days until earnings call
Interact to see
Advertisement

COGT vs MEOBF

Header iconCOGT vs MEOBF Comparison
Open Charts COGT vs MEOBFBanner chart's image
Cogent Biosciences
Price$7.58
Change+$0.17 (+2.29%)
Volume$1.86M
Capitalization863.03M
Mesoblast
Price$0.96
Change-$0.00 (-0.00%)
Volume$1K
Capitalization1.36B
COGT vs MEOBF Comparison Chart in %
Loading...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COGT vs. MEOBF commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a Buy and MEOBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (COGT: $7.58 vs. MEOBF: $0.96)
Brand notoriety: COGT and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 104% vs. MEOBF: 80%
Market capitalization -- COGT: $863.03M vs. MEOBF: $1.36B
COGT [@Biotechnology] is valued at $863.03M. MEOBF’s [@Biotechnology] market capitalization is $1.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 0 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • COGT’s FA Score: 0 green, 5 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, COGT is a better buy in the long-term than MEOBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 6 TA indicator(s) are bullish while MEOBF’s TA Score has 3 bullish TA indicator(s).

  • COGT’s TA Score: 6 bullish, 4 bearish.
  • MEOBF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, COGT is a better buy in the short-term than MEOBF.

Price Growth

COGT (@Biotechnology) experienced а +3.41% price change this week, while MEOBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

COGT is expected to report earnings on Nov 17, 2025.

MEOBF is expected to report earnings on Nov 26, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($1.36B) has a higher market cap than COGT($863M). COGT YTD gains are higher at: -2.821 vs. MEOBF (-56.136). MEOBF has higher annual earnings (EBITDA): -77.78M vs. COGT (-284.04M). COGT has more cash in the bank: 246M vs. MEOBF (37.7M). COGT has less debt than MEOBF: COGT (17.1M) vs MEOBF (126M). MEOBF has higher revenues than COGT: MEOBF (5.67M) vs COGT (0).
COGTMEOBFCOGT / MEOBF
Capitalization863M1.36B63%
EBITDA-284.04M-77.78M365%
Gain YTD-2.821-56.1365%
P/E RatioN/AN/A-
Revenue05.67M-
Total Cash246M37.7M653%
Total Debt17.1M126M14%
FUNDAMENTALS RATINGS
COGT vs MEOBF: Fundamental Ratings
COGT
MEOBF
OUTLOOK RATING
1..100
7350
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
4065
P/E GROWTH RATING
1..100
10061
SEASONALITY SCORE
1..100
26n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COGT's Valuation (81) in the Miscellaneous industry is in the same range as MEOBF (88) in the null industry. This means that COGT’s stock grew similarly to MEOBF’s over the last 12 months.

COGT's Profit vs Risk Rating (67) in the Miscellaneous industry is somewhat better than the same rating for MEOBF (100) in the null industry. This means that COGT’s stock grew somewhat faster than MEOBF’s over the last 12 months.

MEOBF's SMR Rating (95) in the null industry is in the same range as COGT (99) in the Miscellaneous industry. This means that MEOBF’s stock grew similarly to COGT’s over the last 12 months.

COGT's Price Growth Rating (40) in the Miscellaneous industry is in the same range as MEOBF (65) in the null industry. This means that COGT’s stock grew similarly to MEOBF’s over the last 12 months.

MEOBF's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for COGT (100) in the Miscellaneous industry. This means that MEOBF’s stock grew somewhat faster than COGT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTMEOBF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
41%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
52%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
53%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
53%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
50%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGBHX50.580.70
+1.40%
Principal Blue Chip R6
NMULX11.090.10
+0.91%
Neuberger Berman Multi-Cap Opp I
TQSMX23.650.16
+0.68%
T. Rowe Price Integrated US SMCC Eq
CDOYX41.470.21
+0.51%
Columbia Dividend Opportunity Inst3
QMGYX12.750.01
+0.08%
Invesco Advantage International Y

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
+2.29%
SPHDF - COGT
63%
Loosely correlated
N/A
IDYA - COGT
55%
Loosely correlated
+0.82%
XNCR - COGT
55%
Loosely correlated
+1.45%
CGON - COGT
53%
Loosely correlated
+2.09%
SYRE - COGT
53%
Loosely correlated
+1.68%
More

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
+0.40%
COGT - MEOBF
39%
Loosely correlated
+2.29%
MESO - MEOBF
26%
Poorly correlated
-1.66%
KROS - MEOBF
26%
Poorly correlated
+0.30%
More